# RPI.4610 in Treating Patients With Metastatic Kidney Cancer

> **NCT00021021** · PHASE2 · COMPLETED · sponsor: **Ribozyome**

## Conditions studied

- Kidney Cancer

## Interventions

- **BIOLOGICAL:** anti-FLT-1 ribozyme

## Key facts

- **NCT ID:** NCT00021021
- **Lead sponsor:** Ribozyome
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-09
- **Primary completion:** —
- **Final completion:** 2004-02
- **Target enrollment:** — (—)
- **Last updated:** 2013-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00021021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00021021, "RPI.4610 in Treating Patients With Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00021021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*